Brokerages Set Johnson & Johnson (NYSE:JNJ) PT at $210.25

Shares of Johnson & Johnson (NYSE:JNJ) have received an average recommendation of “Moderate Buy” from the twenty-seven ratings firms that are presently covering the company, MarketBeat reports. Nine investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and four have issued a strong buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $211.25.

JNJ has been the subject of several research reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Argus set a $210.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a research note on Monday, October 20th. Finally, The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th.

Johnson & Johnson Trading Down 0.3%

Shares of NYSE:JNJ opened at $206.93 on Friday. The company has a 50 day moving average of $200.25 and a 200-day moving average of $181.93. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a market cap of $498.56 billion, a P/E ratio of 19.97, a P/E/G ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $215.18.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s payout ratio is 50.19%.

Hedge Funds Weigh In On Johnson & Johnson

Institutional investors have recently bought and sold shares of the stock. Abich Financial Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $26,000. Clayton Financial Group LLC acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $28,000. Evolution Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson in the second quarter valued at $27,000. Semmax Financial Advisors Inc. boosted its position in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the period. Finally, Turning Point Benefit Group Inc. purchased a new position in shares of Johnson & Johnson during the third quarter valued at $41,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.